JOHN HOOD,DAVID MARK WALLACE,SUNIL KUMAR KC,CHARLENE BARROGA
申请号：
PT14753569
公开号：
PT2968249T
申请日:
2014.02.21
申请国别(地区):
PT
年份:
2019
代理人:
摘要：
The present disclosure provides ³-diketones or analogs thereof, that activate Wnt/²-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy； osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia； otic disorders like cochlear hair cell loss； eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.
